Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Verena Ramirez Campos"'
Autor:
Peter McAllister, Joshua M. Cohen, Verena Ramirez Campos, Xiaoping Ning, Lindsay Janka, Steve Barash
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-9 (2022)
Abstract Background Migraine is the second leading cause of disability worldwide. Although many preventive treatments reduce migraine frequency and severity, it is unclear whether these treatments reduce migraine-related disability in a clinically me
Externí odkaz:
https://doaj.org/article/c84631b2c8c545b780bd18e1e0043f2c
Autor:
Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow, Christian Lampl
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/2cfef4f751454da4afcac2578f838a35
Autor:
Antoinette MaassenVanDenBrink, Gisela M. Terwindt, Joshua M. Cohen, Steve Barash, Verena Ramirez Campos, Maja Galic, Xiaoping Ning, Mikko Kärppä
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-14 (2021)
Abstract Background Migraine prevalence is age and sex dependent, predominating in women in early and middle adulthood; however, migraine also represents a substantial burden for men and adults of all ages. Thus, understanding this burden and the eff
Externí odkaz:
https://doaj.org/article/3aa93823035d49df961e4babee9f0114
Autor:
Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow, Christian Lampl
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-12 (2021)
Abstract Background Although migraine is less common in older people, preventive treatment of migraine in these individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy. Additionally, evidence for migraine tr
Externí odkaz:
https://doaj.org/article/85e212b2b1294997a15ab3ee23884b36
Autor:
Kimberly D. Mackenzie, Mario Ortega, Yoel Kessler, Verena Ramirez Campos, Lynda J. Krasenbaum, Karen Carr, Xiaoping Ning, Jennifer Stratton
Publikováno v:
Frontiers in Physiology, Vol 13 (2022)
Calcitonin gene-related peptide (CGRP) pathway-targeted treatments have been shown to be efficacious in the prevention of episodic and chronic migraine. Currently approved therapies include monoclonal antibodies (mAbs) that target CGRP (eptinezumab,
Externí odkaz:
https://doaj.org/article/f0c7a8dc921146898c7fe90a37c8d9e7
Autor:
Messoud Ashina, Joshua M. Cohen, Maja Galic, Verena Ramirez Campos, Steve Barash, Xiaoping Ning, Yoel Kessler, Lindsay Janka, Hans-Christoph Diener
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-13 (2021)
Abstract Background Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine. In this study, we evaluated the long-term effi
Externí odkaz:
https://doaj.org/article/876b75245bac4ca8978ec875cf82f837
Autor:
Egilius L. H. Spierings, Mikko Kärppä, Xiaoping Ning, Joshua M. Cohen, Verena Ramirez Campos, Ronghua Yang, Uwe Reuter
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-12 (2021)
Abstract Background The FOCUS study evaluated the efficacy of migraine preventive medications across different countries within the same patient population, particularly for patients with difficult-to-treat migraine. These prespecified subgroup analy
Externí odkaz:
https://doaj.org/article/8fb2e15f724647799b90d9afe86d3a83
Autor:
Joshua M. Cohen, Xiaoping Ning, Yoel Kessler, Michele Rasamoelisolo, Verena Ramirez Campos, Michael J. Seminerio, Lynda J. Krasenbaum, Honglue Shen, Jennifer Stratton
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-8 (2021)
Abstract Background Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have been shown to be effective in migraine prevention. Eptinezumab, erenumab, fremanezumab, and galcanezumb have shown efficacy in clinical
Externí odkaz:
https://doaj.org/article/30df5c3385fd4b69b2d270618060643e
Autor:
Dawn C. Buse, Sanjay K. Gandhi, Joshua M. Cohen, Verena Ramirez-Campos, Blaine Cloud, Ronghua Yang, Robert P. Cowan
Publikováno v:
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background The long-term safety and efficacy of fremanezumab were evaluated in a 52-week extension study (NCT02638103). Patient satisfaction with fremanezumab, dosing preferences, and patient-reported outcomes were assessed in a subpopulatio
Externí odkaz:
https://doaj.org/article/8464cea9ead14f2fb27123c5dc3e888b
Autor:
Stephen D. Silberstein, Shoshana Reshef, Joshua M. Cohen, Sanjay Gandhi, Michael Seminerio, Verena Ramirez Campos, Yoel Kessler, Stephen F. Thompson, Andrew Blumenfeld
Publikováno v:
Advances in Therapy. 40:445-459
Through 2018, three calcitonin gene-related peptide pathway-targeted monoclonal antibodies (CGRP mAbs) had received US Food and Drug Administration (FDA) approval for migraine prevention: erenumab, fremanezumab, and galcanezumab.This retrospective an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727d63d4d6216987d538e73b8d27cb05
https://doi.org/10.1007/s12325-022-02346-4
https://doi.org/10.1007/s12325-022-02346-4